Dr. Monchamp is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
929 SW Simpson Ave
Suite 220
Bend, OR 97702Phone+1 541-317-5600Fax+1 541-317-5676
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 2003 - 2004
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
New York Medical CollegeClass of 2000
Certifications & Licensure
CA State Medical License 2001 - Present
OR State Medical License 2006 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Intergy EHR, Vitera Healthcare Solutions, LLC, 2013
- CMS Meaningful Use Stage 1 Certification Intergy EHR, Greenway Health, LLC, 2011
Clinical Trials
- The Effects of Exenatide After Gastric Restriction Start of enrollment: 2009 Feb 01
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes Start of enrollment: 2022 May 19
Roles: Contact
Publications & Presentations
PubMed
- 288 citationsPancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetesYoshifumi Saisho, Alexandra E. Butler, Juris J. Meier, Travis Monchamp, M. Allen-Auerbach
Clinical Anatomy. 2007-11-01 - 497 citationsβ-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of β-Cell Mass in HumansJuris J. Meier, Alexandra E. Butler, Yoshifumi Saisho, Travis Monchamp, Ryan Galasso
Diabetes. 2008-06-01 - 15 citationsEfficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections...Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki, Daniel Kramer, Francois Delalande
Diabetes Technology & Therapeutics. 2020-01-22
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
